Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
SPRO compared with LYEL: revenue, margins and what each company keeps, and the suppliers and customers both name
SPRO
Spero Therapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
LYEL
Lyell Immunopharma, Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
SPRO
Spero Therapeutics, Inc.
vs
LYEL
Lyell Immunopharma, Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Supply-chain overlap
Desk
News
Calendar
Saved
Search
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only SPRO
7
PFE
Pfizer
supplier
GSK
GSK
customer
—
Meiji
unlisted
supplier
—
Cantab Anti-Infectives
unlisted
supplier
3 more · SPRO chain
›
Shared
0
No shared counterparties.
Only LYEL
11
—
City of Hope Comprehensive Cancer Center
unlisted
supplier
—
Dana Farber Cancer Institute
unlisted
supplier
—
Innovative Cellular Therapeutics Holdings Limited and Innovative Cellular Therapeutics, Inc. (together, ICT)
unlisted
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
supplier
—
Miltenyi CliniMACS PRODIGY ®
unlisted
supplier
7 more · LYEL chain
›
SPRO
Spero Therapeutics, Inc.
Change
1.04
▼
−2.08%
Mkt cap
$61.7M
Revenue
$258,000
Q1 FY26
Revenue
$67M
FY25
LYEL
Lyell Immunopharma, Inc.
Change
11.02
▼
−0.21%
Regular session
Nov 2 '26
Mkt cap
$270.5M
Revenue
$4,000
Q2 FY26
Revenue
$36,000
FY25
vs
Compare
Regular session
Nov 2 '26
SPRO
Spero Therapeutics, Inc.
vs
LYEL
Lyell Immunopharma, Inc.
1.04
▼
−2.08%
Price
11.02
▼
−0.21%
$61.7M
Mkt cap
$270.5M
Q1 FY26
$258,000
Revenue
$4,000
Q2 FY26
FY25
$67M
Revenue
$36,000
FY25
Change
Change
SPRO
1.04
▼
−2.08%
vs
LYEL
11.02
▼
−0.21%
Regular session
Nov 2 '26